Business Enterprise Trust: Merck & Co., Inc. (A)
Teaching Notes
Synopsis
A scientist at Merck finds that a drug the company has developed to treat a parasite that
infects animals may hold the key to treating a similar problem with human beings. The
illness in humans is called “River Blindness”, it afflicts 18 million people (with 85
million at risk), and has horrible effects on its victims – worms that reproduce and spread
through the body of the victim cause tremendous discomfort and itching that lead many
to commit suicide, and it eventually causes blindness. The central problem is that the
populations affected by this disease are all in developing countries, they are poor, and
they are unlikely to be able to pay for a drug. Given Merck’s mission to make medicine
that is for the people, not the profits, how should they respond?
Objective
This case provides a great opportunity to think about the themes presented in Chapter 3,
particularly the nature of business, the purpose of the corporation, and responsibilities to
stakeholders. Merck stands as an example of a company that has a mission which extends
beyond making money, but this case raises a paradox – if the profits don’t (clearly)
follow, to what extent can Merck pursue medical leads and remain a viable business? Is
Questions for Discussion
1. How should Roy Vagelos think about this problem? What are some possible
approaches to take to framing what is going on here?
2. Does Merck have an obligation to do something here? Does its knowledge create
an obligation to act? If so, does that extend to an obligation to spend between
$100-200 million of its resources to help?
3. What should be on Vagelos’ radar screen as he thinks about this decision? What
specific considerations should he at least note before he gets to a decision?
a. Which stakeholders should he think about? What is their interest?
b. What is at stake for Vagelos? How will this decision shape him and his
character?